Study Finds a Key Switch Behind Harmful Inflammation

Inflammation is one of the body’s most important defenses. When you’re injured or fighting an infection, immune cells release signals that help contain the threat and begin repairing the damage. Usually, that response eventually quiets down.

The problem comes when inflammation stays switched on.

Persistent inflammation plays a role in numerous chronic diseases, but scientists are still working out exactly what keeps some of these inflammatory signals going. Now, researchers at Johns Hopkins Medicine say they have identified one protein that may help flip an important part of that inflammatory response into action.

In a 2026 study published in PLOS One, researchers found that a protein called resistin can activate the NLRP3 inflammasome, a molecular system inside immune cells that helps trigger inflammation. Even more interestingly, blocking resistin reduced that response in laboratory experiments.

The finding is still early-stage research, not a new treatment for chronic inflammation. But it gives scientists a clearer look at one of the molecular switches that may keep harmful inflammatory pathways active.

What Is the NLRP3 Inflammasome?

The name sounds complicated, but the basic idea is fairly simple.

Macrophages are immune cells that help detect infections, damaged cells, and other potential threats. Inside them are molecular systems called inflammasomes, which act somewhat like internal alarm systems.

One of the best-studied is the NLRP3 inflammasome. When activated, it helps trigger the release of inflammatory signaling molecules, including IL-1β and IL-18. Those signals are useful when the immune system needs to respond to a threat, but excessive or persistent NLRP3 activity has been implicated in numerous inflammatory diseases.

Researchers already knew that another protein, called resistin, was associated with inflammation. In humans, resistin is produced largely by immune cells, including macrophages, and elevated levels have been observed in several inflammatory conditions.

What wasn’t clear was exactly how resistin and NLRP3 were connected.

The Johns Hopkins team set out to find out.

Resistin Appears to Flip the Switch in Two Steps

The researchers found that resistin doesn’t simply turn NLRP3 on with a single signal. Instead, it appears to help activate the system through two related processes.

First, resistin increased the production and release of a protein called HMGB1. That helped prepare, or “prime,” macrophages to produce components needed for the inflammasome response.

Resistin also interacted with an enzyme called Bruton’s tyrosine kinase, or BTK. This helped activate NLRP3 itself, ultimately leading the macrophages to release IL-1β and IL-18.

In other words, resistin appeared to help prepare the inflammatory machinery and then help switch it on.

That provides a potential explanation for something researchers had observed for years: why elevated resistin and heightened inflammation so often appear together.

Researchers Found the Same Pathway in Diseased Human Lungs

The team then looked for evidence that this pathway wasn’t limited to cells in a laboratory.

They examined lung tissue from people with pulmonary hypertension, a group of conditions in which blood pressure in the vessels supplying the lungs becomes abnormally high. The disease can place increasing strain on the heart and cause symptoms including shortness of breath, fatigue, chest discomfort, and fainting.

In lung samples from patients with pulmonary hypertension, researchers found increased colocalization of resistin, BTK, and NLRP3 within macrophages. Similar components of the pathway were also studied in a mouse model of hypoxia-induced pulmonary hypertension.

That’s important because it suggests the molecular pathway identified in the laboratory may also be active in actual disease.

It does not, however, prove that elevated resistin causes pulmonary hypertension. The researchers used the condition as a model for investigating the inflammatory pathway, and clinical studies would be needed to establish whether targeting resistin improves disease in people.

What Happened When Researchers Blocked Resistin?

This may be the most interesting part of the study.

Researchers used an antibody designed to bind to resistin. When resistin was blocked, activation of the NLRP3 pathway decreased in their experiments. The researchers also investigated antibody blockade in their mouse experiments.

That raises the possibility that resistin could eventually become a therapeutic target.

Rather than broadly suppressing inflammation, researchers could potentially interfere with a specific signal helping drive an inflammatory pathway. That’s an appealing idea because inflammation itself isn’t inherently bad. The immune system still needs it to fight infections and repair damaged tissue.

But there’s a substantial distance between identifying a promising molecular target and developing a treatment that is safe and effective in humans.

This Isn’t an Anti-Inflammatory Treatment Yet

The study combined experiments in human macrophage-derived cells, mouse models, and analysis of human lung tissue. It was not a clinical trial of a resistin-blocking drug.

No evidence from this study shows that blocking resistin can treat chronic inflammatory disease in people.

It also remains unclear how important this pathway is across different conditions. NLRP3 has been implicated in numerous diseases, but that doesn’t mean resistin is necessarily driving its activation to the same degree in each one.

The pulmonary hypertension findings are similarly suggestive rather than definitive. Finding resistin, BTK, and NLRP3 together in diseased tissue strengthens the biological case for the pathway, but it doesn’t establish which came first or whether blocking resistin would improve patient outcomes.

The Bottom Line

The discovery doesn’t provide a new way to treat chronic inflammation today. What it provides is something more fundamental: a clearer explanation for how one inflammatory signal may get switched on.

Researchers found that human resistin can help prime and activate the NLRP3 inflammasome in macrophages through a defined molecular pathway. They also found signs of that pathway in lung tissue from people with pulmonary hypertension and showed that interfering with resistin could reduce inflammasome activation experimentally.

The next question is whether that mechanism matters enough in human disease to become a useful treatment target. If future research confirms it does, resistin could give scientists a more precise way of interfering with harmful inflammation without simply trying to suppress the immune response as a whole.

For now, the important discovery isn’t a new anti-inflammatory drug. It’s a new potential target for one.

Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.

AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.